Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.
Follow-Up Questions
What is Cynata Therapeutics Ltd (CYYNF)'s P/E Ratio?
The P/E ratio of Cynata Therapeutics Ltd is N/A
Who is the CEO of Cynata Therapeutics Ltd?
Dr. Kilian Kelly is the Chief Executive Officer of Cynata Therapeutics Ltd, joining the firm since 2019.
What is the price performance of CYYNF stock?
The current price of CYYNF is 0.118, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Cynata Therapeutics Ltd?
Cynata Therapeutics Ltd belongs to Biotechnology industry and the sector is Health Care
What is Cynata Therapeutics Ltd market cap?
Cynata Therapeutics Ltd's current market cap is $28
Is Cynata Therapeutics Ltd a buy, sell, or hold?
According to wall street analysts, 0 analysts have made analyst ratings for Cynata Therapeutics Ltd, including 1 strong buy, 3 buy, 1 hold, 0 sell, and 1 strong sell
